BOC Sciences offers specialized GalNAc-siRNA conjugates, designed to enhance the delivery and efficacy of RNA interference (RNAi) therapeutics. These conjugates leverage the targeting capability of N-acetylgalactosamine (GalNAc) to deliver small interfering RNA (siRNA) specifically to liver cells via the asialoglycoprotein receptor (ASGPR). By improving the stability and cellular uptake of siRNA, BOC Sciences' GalNAc-siRNA conjugates provide a powerful tool for gene silencing applications in liver-related diseases, ensuring precise and efficient therapeutic outcomes.
29 май 2024
